cabozantinib
UkraineDrugs containing this active substance
-
The drug is indicated for the treatment of adults with advanced renal cell carcinoma (including both treatment-naive patients and those previously treated with vascular endothelial growth factor receptor inhibitors), as well as for monotherapy of hepatocellular carcinoma in patients previously treated with sorafenib.
Form: tablets, film-coated
Active substance Dosage cabozantinib 20 mg ATC: L01EX07
Manufacturer: Pateon Inc. (manufacturing, primary and secondary packaging, testing at release and stability)
-
The drug is prescribed for the treatment of advanced renal cell carcinoma (in adults who have not previously received treatment, as well as after prior therapy with other agents), and also as monotherapy for hepatocellular carcinoma in adults who have previously received sorafenib.
Form: tablets, film-coated
Active substance Dosage cabozantinib 40 mg ATC: L01EX07
Manufacturer: Pateon Inc. (manufacturing, primary and secondary packaging, testing at release and stability)
-
The drug is prescribed for the treatment of advanced renal cell carcinoma (in adults who have not previously received treatment or have received drugs that affect vascular endothelial growth factor) and as monotherapy for hepatocellular carcinoma (in adults who have previously received sorafenib).
Form: tablets, film-coated
Active substance Dosage cabozantinib 60 mg ATC: L01EX07
Manufacturer: Pateon Inc. (manufacturing, primary and secondary packaging, testing at release and stability)